• Alopi Patel, Ami Shah, Anthony Apigo, Hung-Mo Lin, Yuxia Ouyang, Kristy Huang, Seana Friedman, Mekeleya Yimen, John D Puskas, and Himani V Bhatt.
• Department of Anesthesiology, Perioperative and Pain Medicine, Mount Sinai Morningside Medical Center, New York, NY. Electronic address: alopipatelmd@gmail.com.
• J. Cardiothorac. Vasc. Anesth. 2024 Jan 1; 38 (1): 183188183-188.

ObjectivesDetermine the effect of low-dose pregabalin in the perioperative enhanced recovery after cardiac surgery protocol.DesignPre-post observational study.SettingTertiary care hospital.ParticipantsPatients undergoing off-pump coronary artery bypass graft procedures.InterventionsPregabalin 75 mg BID for 48 hours postoperatively versus no pregabalin in a perioperative setting.Measurements And Main ResultsPerioperative opioid use, pain scores, length of stay, time to extubation, and mortality were all measured. Descriptive data were presented as mean (SD), median (IQR), or N (%). Ordinal and continuous data used the t-test or Kruskal-Wallis test. Categorical data were compared between groups using the chi-square test or Fisher's exact test, as appropriate. Low-dose pregabalin administration (75 mg twice daily for 48 hours after surgery) was associated with a clinically significant reduction in opioid consumption on postoperative day 0 by 30.6%, with a median requirement of 318 (233, 397) morphine milligram equivalents (MME) in the pregabalin group compared with 458 (375, 526) MME in the control group (p < 0.001). There was no significant difference in pain scores between the groups with the exception at 0-to-12 hours, during which the pregabalin group had greater pain scores (median 3.32 [1.65, 4.36] v 2.0 [0, 3.25], p = 0.013) (Table 3). Moreover, there was no significant difference in pain scores on postoperative day 1 (p = 0.492), day 2 (p = 0.442), day 3 (p = 0.237), and day 4 (p = 0.649). The difference in average Richmond Agitation Sedation Score scores was also not statistically significant between groups at 12 hours (p = 0.954) and at 24 hours (p = 0.301). The pregabalin group had no increased incidence of adverse events or any significant differences in intensive care unit length of stay, time to extubation, or mortality.ConclusionsIn this evaluation of perioperative pregabalin administration for patients requiring cardiac surgery, pregabalin reduced postoperative opioid use, with significant reductions on postoperative day 0, and without any significant increase in adverse reactions. However, no differences in intensive care unit length of stay, time to extubation, or mortality were noted. The implementation of low-dose perioperative pregabalin within an Enhanced Recovery After Cardiac Surgery protocol may be effective at reducing postoperative opioid use in the immediate postoperative period, and may be safe with regard to adverse events. Ideal dosing strategies have not been determined; thus, further randomized control trials with an emphasis on limiting confounding factors need to be conducted.Copyright © 2023 Elsevier Inc. All rights reserved.

30 keywords...

hide…